Protalix Biotherapeutics Inc
$ 3.00
-4.46%
24 Feb - close price
- Market Cap 252,523,000 USD
- Current Price $ 3.00
- High / Low $ 3.17 / 2.99
- Stock P/E 39.25
- Book Value 0.66
- EPS 0.08
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.13 %
- 52 Week High 3.19
- 52 Week Low 1.32
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Analyst Target Price
$11.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-08 | 2025-03-12 | 2024-11-04 | 2024-08-14 | 2024-05-10 | 2024-03-14 | 2023-11-06 | 2023-08-07 | 2023-05-04 | 2023-02-27 |
| Reported EPS | 0.03 | -0.04 | -0.05 | 0.09 | 0.03 | -0.03 | -0.06 | -0.07 | -0.04 | 0.21 | -0.05 | -0.07 |
| Estimated EPS | 0.07 | 0.11 | -0.02 | 0.07 | 0.06 | 0.02 | -0.02 | -0.03 | -0.07 | -0.04 | -0.05 | -0.15 |
| Surprise | -0.04 | -0.15 | -0.03 | 0.02 | -0.03 | -0.05 | -0.04 | -0.04 | 0.03 | 0.25 | 0 | 0.08 |
| Surprise Percentage | -57.1429% | -136.3636% | -150% | 28.5714% | -50% | -250% | -200% | -133.3333% | 42.8571% | 625% | 0% | 53.3333% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.0 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLX
2026-02-24 13:53:14
Protalix Biotherapeutics, Inc. has reached a new 52-week high of $3.19, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company's stock price has increased by 163.87% over the past year, significantly outperforming the S&P 500. It maintains a price-to-earnings ratio of 27.00 and a market capitalization of $246 million.
2026-02-11 21:57:33
Protalix BioTherapeutics, Inc. announced a positive CHMP opinion for Elfabrio®'s new 2 mg/kg every 4 weeks dosing regimen, aimed at treating Fabry disease in the EU. This decision is expected to be approved by the European Commission by the end of March 2026, leading to a $25 million milestone payment for Protalix from Chiesi. The new regimen is anticipated to reduce treatment burden and improve the quality of life for patients.
2026-02-05 09:57:33
Protalix BioTherapeutics (NYSE:PLX) shares surged 6.2% in midday trading on significant volume, reaching $2.90 after previously closing at $2.73. This comes despite HC Wainwright reducing its price target for PLX from $15 to $12, while maintaining a "Buy" rating. Insider activity also shows CEO Dror Bashan recently increased his holdings by 42.26%, acquiring 56,000 shares.
2026-02-04 18:08:00
The one-year price target for Protalix BioTherapeutics (PLX) has been lowered by 12.00% to $11.22 per share, down from $12.75. This target represents a significant increase of 310.99% from its latest closing price of $2.73. Institutional ownership in PLX has increased, with 132 funds reporting positions, and a bullish put/call ratio of 0.08.
2026-02-04 11:58:13
Protalix Biotherapeutics (PRTX) has formed a Golden Cross, a technical indicator signaling potential bullish momentum. The stock has seen a significant year-to-date gain of 51.67%, outperforming the S&P 500. This positive trend is further supported by bullish signals from Moving Averages, MACD, and Bollinger Bands, suggesting a potential turnaround for the company.
2026-02-04 09:29:42
Protalix BioTherapeutics, a clinical and commercial pharmaceutical company, uses its proprietary ProCellEx plant-based system for therapeutic protein production. The company has two commercial products: Elelyso for Gaucher Disease and Elfabrio, approved in May 2023, which is expected to command a premium due to improvements over market leaders. Protalix also has additional drug candidates in earlier development stages, including PRX-115 for refractory gout and PRX-119 for NETs-related diseases.
